Ramoplanin

Summary

Ramoplanin is an investigational glycodepsipeptide antibiotic administered orally. It is being studied for the prevention of bloodstream infection in patients colonized with vancomycin‑resistant enterococci (VRE) and for treatment of Clostridium difficile‑associated diarrhea. The compound shows bactericidal activity against a broad range of Gram‑positive bacteria, including strains resistant to vancomycin, methicillin, and other classes.

Mechanism of Action

Ramoplanin acts by binding to lipid II and related peptidoglycan precursors, sequestering them at the bacterial membrane. This occlusion prevents the substrates from being accessed by the late‑stage enzymes MurG and the transglycosylases that assemble the cell wall, thereby halting peptidoglycan synthesis and causing rapid bacterial death. The mechanism is distinct from that of glycopeptides such as vancomycin.

What the Research Shows

Early in‑vitro studies demonstrated potent bactericidal activity of ramoplanin against Gram‑positive aerobic and anaerobic organisms, including VRE, MRSA, and C. difficile, with no reported cross‑resistance to vancomycin or other glycopeptides. A 2004 review noted that ramoplanin is not systemically absorbed after oral dosing and is being evaluated for decolonization of VRE carriers. Subsequent reviews (2005, 2008) described ongoing oral clinical trials for C. difficile‑associated diarrhea and for preventing VRE bloodstream infection. A 2017 article cited ramoplanin among poorly absorbed agents that may influence C. difficile spore outgrowth, highlighting its potential role in reducing recurrence. To date, no clinical efficacy data have been published, and the compound remains investigational.

Reported Benefits

Ramoplanin offers bactericidal activity against resistant Gram‑positive pathogens, including VRE and MRSA, where many agents are only bacteriostatic. In vitro susceptibility data show effectiveness against strains resistant to glycopeptides and macrolides, and no cross‑resistance has been documented. Its poor oral absorption limits systemic exposure, potentially reducing toxicity while allowing high concentrations in the gut lumen for infections such as C. difficile.

Limitations of the Evidence

The drug is still investigational and has not received regulatory approval for any indication. Clinical evidence is limited to early‑phase trials focused on VRE decolonization and C. difficile diarrhea, with no published efficacy outcomes. Poor systemic absorption restricts its use to gastrointestinal applications and precludes treatment of invasive infections. Long‑term safety and resistance development remain uncharacterized.

Safety Considerations

Published reviews report minimal adverse effects and no documented drug‑drug interactions, likely due to the compound's lack of systemic absorption. However, safety data are derived from early trials and pre‑clinical studies; comprehensive safety profiling has not yet been completed. Caution is warranted until larger clinical studies confirm tolerability.

How It Is Administered

Ramoplanin is formulated for oral administration as a poorly absorbed preparation. Current investigational protocols employ oral dosing to achieve high concentrations in the intestinal lumen for decolonization of VRE and treatment of C. difficile‑associated diarrhea. No parenteral or systemic formulations are reported.

Routes of Administration

Goals & Uses

• Eradication of VRE intestinal colonizationAntimicrobial / DecolonizationModerate
• Clostridioides difficile infectionInfectionModerate
• Prevention of bacteremia in immunocompromised patients colonized with VREAntimicrobial / ProphylaxisLow
• Vancomycin‑resistant Enterococci (VRE)InfectionModerate
• Treatment of Clostridioides difficile infectionAntimicrobialModerate
• Activity against MRSAAntimicrobialLow
• Methicillin‑resistant Staphylococcus aureus (MRSA)InfectionModerate

Contraindications

• Hypersensitivity to ramoplaninAllergyHigh
• Severe renal impairmentOrganModerateKidney function concerns
• Known hypersensitivity to ramoplanin or glycodepsipeptidesAllergyHigh

Adverse Effects

• RashDermatologicUncommonSkin eruption or discoloration
• Injection site reactions (if parenteral)LocalUnknown
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalUncommonForceful expulsion of stomach contents
• DiarrheaGastrointestinalCommonLoose or frequent stools
• Abdominal painGastrointestinalUncommonPain or discomfort in the abdomen

Drug Interactions

• Antacids (aluminum/magnesium)Moderate
• Oral anticoagulants (e.g., warfarin)Low
• Broad‑spectrum antibioticsLow

Population Constraints

• Severe gastrointestinal mucosal damageGastrointestinalRelative
• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization.
• United StatesInvestigationalPhase II oral trials for C. difficile; not FDA‑approved.
• United KingdomUnapprovedNo licensing; used only in research settings.

Not approved by FDA, EMA or MHRA; used only in clinical trials and limited compassionate‑use programs.

Evidence & Sources

• Approaches to vancomycin-resistant enterococci
  Journal ArticleModerateTorres-Viera C, Dembry LM2004-01-01T00:00:00.000000Z
• Chemistry and biology of the ramoplanin family of peptide antibiotics
  Journal ArticleModerateMcCafferty DG, et al.2002-01-01T00:00:00.000000Z
• Treatment of Clostridium difficile infection
  Journal ArticleModerateGerding DN, Muto CA, Owens RC Jr2008-01-01T00:00:00.000000Z
• Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies
  Journal ArticleModerateBoger DL2001-01-01T00:00:00.000000Z
• Microbiologic factors affecting Clostridium difficile recurrence
  Journal ArticleModerateChilton CH, Pickering DS, Freeman J2018-01-01T00:00:00.000000Z
• Ramoplanin: a lipoglycodepsipeptide antibiotic
  Journal ArticleModerateFarver DK, Hedge DD, Lee SC2005-01-01T00:00:00.000000Z

Frequently Asked Questions